X-linked hyper IgM syndrome (XHM) is a combined immune deficiency disorder caused by genetic alterations in CD40 ligand. The purpose of this study was to investigate the safety and efficacy of recombinant CD40 ligand (rCD40L) in the treatment of the disease. Three children were administered rCD40L subcutaneously three times per week at 0.03 mg/kg for 22 weeks, and after a 12 week drug free interval, the dose was increased to 0.05 mg/kg for an additional 22 weeks of treatment. Although specific antibody responses to T cell dependant antigens was lacking, administration of rCD40 resulted in acquisition of the capacity to mount cutaneous delayed type hypersensitivity reactions that disappeared during the drug free interval as well as the post-biologic follow-up period. With rCD40L treatment, patient T cells developed a new capacity to respond to T cell mitogens with synthesis of IFN-γ and TNF-α. Intracellular cytokine staining studies showed that both CD4+ and CD8+ T cells participated in this response.
Introduction
X-linked hyper-IgM syndrome (XHM) is a rare inherited immune deficiency disorder caused by mutations in the gene encoding CD40 ligand (CD40L [CD154]). [1] [2] [3] The cognate interaction between CD40L expressed on activated CD4 + T cells and CD40 expressed constitutively on B cells leads to B cell proliferation, somatic hypermutation (SHM) in the immunoglobulin variable region, and immunoglobulin class switch recombination (CSR) from IgM to IgG, IgA, and IgE. [4] [5] [6] Humans with mutations in the genes encoding CD40L have skewed IgM antibody responses and a markedly diminished or absent IgG response to protein antigens. [7] [8] [9] CD40 engagement on the surface of dendritic cells also influences dendritic cell maturation and activation. 8, 10 It thus promotes the expression of factors that promote T cell priming such as co-stimulatory molecules B7.1 (CD80) and B7.2 (CD86), IL-12 secretion, and the release of chemokines. 10, 11 Indeed, humans and mice with CD40L deficiency exhibit defective T cell function that manifests by a marked predisposition to develop opportunistic infections with Pneumocystis jerovicii, Toxoplasma gondii, and Cryptosporidium as well as an increased tendency to develop malignancies. [12] [13] [14] [15] The IgG/IgA deficiency and associated humoral immune abnormalities in patients with XHM is effectively controlled by gamma globulin replacement therapy (IVIG therapy). 13, 16 However, despite such treatment the majority of patients die in the second decade of life as a consequence of impaired T cell function. 13, 17 Bone marrow transplantation is an effective treatment for patients with XHM, especially if performed early in life before the onset of secondary opportunistic infection, 18, 19 although the need for matched related donors and the associated morbidity and mortality of the transplant impact on its clinical application. 20, 21 For personal use only. on October 24, 2017 . by guest www.bloodjournal.org From Identification of CD40L as an important signaling molecule led to the development of a soluble form of recombinant CD40 ligand (rCD40L) that could be used in various clinical situations. 22, 23 This trimeric form of human rCD40L was generated using an isoleucine zipper that is capable of activating the CD40 receptor (Amgen-Seattle). We first conducted pre-clinical studies in a murine model of XHM in which the CD40 ligand was disrupted through genetic engineering revealed that administration of CD40 agonists or recombinant murine CD40L trimer reversed the core immunologic abnormalities. More specifically, treated animals exhibited improved survival and were able to mount antigen-specific antibody responses. Furthermore, we found that in vitro addition of rCD40L induced monocytes in peripheral blood mononuclear cells of XHM patients to produce IL-12 as well as upregulate the expression of CD80/ 86, which in turn allowed their T cells to produce TNF-α and IFN-γ 24 . Stimulated by these observations, we therefore next performed an open label treatment study of recombinant human CD40L replacement at two successive doses in patients with XHM.
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Methods

Patients and Protocols
Patients were studied at the Clinical Center, NIAID, NIH (protocol # 00-I-006). The diagnosis of XHM was established by medical and family history, immunoglobulin profile, and by sequencing the gene encoding CD40 ligand. Three XHM patients ages 8, 13, and 10 years were enrolled in the study. At the time of enrollment, patients underwent a physical examination, complete blood count, serum chemistry screening and computerized tomograms (CT) of the chest and abdomen to establish their baseline medical condition, and, when possible, a lymph node biopsy. Blood was collected during the treatment period, and a chest CT and lymph node biopsy was performed at the end of treatment. Patients were maintained on gamma globulin substitution therapy (IVIG) and antibiotic prophylaxis with trimethoprim/sufamethazole; no adjustments in dose or frequency of gamma globulin infusions were permitted during the study period. The Institutional Review Board of NIAID approved the open protocol and informed assent and consent was obtained from all patients and their parents, respectively, before enrollment in the study in accordance with the Declaration of Helsinki.
Treatment
The three XHIM patients received rCD40L by subcutaneous injection on alternate days (Monday, Wednesday, Friday) on a single step dose escalation schedule. Each patient received rCD40L at 0.03 mg/kg for 22 weeks, followed by a 12 week drug free interval, and then a second course of rCD40L at 0.05 mg/kg for an additional 22 weeks. The treatment schedule was based on data from two other XHM patients (see below), previous studies in cancer patients, and from pre-clinical development research in non-human primates. Patients were monitored weekly for For personal use only. on October 24, 2017. by guest www.bloodjournal.org From evidence of drug toxicity using the National Cancer Institute (NCI) Common Toxicity Criteria version 2.0 (available from http://ctep.cancer.gov/) during treatment, and every 4 weeks during the post-biologic observation period. Recurrent grade 2 toxicity or any grade 3 or 4 toxicity was defined as a major adverse event and required discontinuation from the study. Isolated grade 2 toxicity was not considered a major adverse event but did necessitate withholding rCD40L treatment until the toxicity resolved.
To establish an appropriate and safe rCD40L dose, two XHM patients who were not subsequently included in the study were initially evaluated for toxicity upon administration of rCD40L. These patients were administered six doses of rCD40L at 0.01 mg/ kg/ day on a Monday, Wednesday, and Friday schedule for 2 weeks, followed by a drug-free week. They were then administered 0.03 mg/ kg/ day of rCD40L using the same schedule for three weeks followed by a drug-free week (for a total of 21 additional doses). rCD40L was well tolerated at both dose levels, thus permitting the study of the three patients that are the focus of this report.
Immune Assessment
Prior to beginning the study, the patients were assessed for their ability to mount delayed type hypersensitivity reactions (DTH) by subcutaneous injection of purified candida and mumps "recall" antigens. Intra-cutaneous DTH skin tests with these proteins were repeated at 10 and 20 weeks into both treatment periods, and at 8 weeks into the drug free treatment period as well as after cessation of rCD40L administration. In addition, T cells responses to recall antigens was evaluated by immunizing the patients with 2.5 mg of keyhole limpet hemocyanin (KLH) during weeks 8, 12, and 16 of rCD40L administration followed by intra-cutaneous DTH skin testing. In vitro cytokine responses were evaluated prior to and during the course of the study.
Peripheral blood mononuclear cells (PBMC) were obtained using Ficoll-Hypaque density gradient lymphocyte separation medium (Pharmacia Biotech, Inc., Piscataway, New Jersey, USA) and standard techniques. 25 PBMCs were stimulated in vitro with anti-CD3 antibody, according to the manufacturer's instructions. Intracellular cytokine detection was performed as previously described. 27 Mutation analysis in B cells was performed by methods previously described.
28
Animals CD40L-deficient mice were generated as previously described 29 . Mice were maintained under specific pathogen-free conditions. All experimental procedures were in accordance with the 
RESULTS
Murine CD40 ligand treatment improves survival of CD40L deficient mice
In keeping with the immunologic findings in XHM patients, CD40 ligand knockout (CD40L KO) mice are incapable of neutralizing antibody responses and are susceptible to pulmonary pneumocystis infection as a consequence of defects in T cell priming. To determine if treatment with murine CD40L treatment ameliorates the disease phenotype in CD40L KO mice, two groups were administered murine CD40L at doses denoted in the figure 1. A similar aged control group received treatment with buffer and was housed in the same specific pathogen-free facility.
Mice were monitored for morbidity and mortality until day 450 or death. Murine CD40L treatment improved the survival incidence of Group 1 (42%) and Group 2 (89%) CD40L KO compared to the control CD40L KO group (0%) at the termination of the experiment on day 450.
Mean survival times for the two groups treated with CD40L are significantly greater (p <0.01) than the control group. The vast majority of control CD40L KO mice and group 1 CD40L KO mice died from pulmonary pneumocystis infection. Thus the improved survival in CD40L deficient mice with murine CD40L treatment is dose dependent and is likely reflective of restored cellular immunity. Murine CD40L treatment also restored immunoglobulin class switch and antigen specific antibody responses in CD40L KO mice (Supplemental table 1 and 2). Thus treatment with murine CD40L restores the core immunologic abnormalities in CD40L deficient mice and these findings are consistent with a previous study utilizing a CD40 agonist antibody 30 .
Patient Characteristics
The three XHM patients enrolled in this study had histories of recurrent otitis media and frequent upper respiratory bacterial infections that occasionally required hospitalization. One patient developed P. jirovecii infection at 6 months of age and another developed disseminated coccidioidomycosis at 5 years of age that ultimately required maintenance fluconazole suppressive therapy. Laboratory evaluation revealed that the three patients had normal numbers of B cells and T cells but in each case these cell populations exhibited evidence of failure of immunoglobulin class switch: the B cells expressed surface IgD and IgM but did not express surface IgG or IgA. In addition, as previously described, the CD4+ T cells were predominantly CD45RA+ with very limited CD45RO+ expression. 24 All patients had markedly decreased IgG levels (<250 mg/dl) prior to initiation of monthly intravenous immunoglobulin (IVIG) therapy and all were maintained on antibiotic prophylaxis for Pneumocystis pneumonia. This treatment regimen was continued during the study.
All three patients completed both phases of rCD40L treatment as specified in the protocol without serious adverse events and each patient received a total of 132 subcutaneous injections.
In previous studies of cancer patients, dose-related, transient serum elevations in liver transaminases were seen during treatment with rCD40L 31 . In that study grade 3 or 4 elevations in ALT were observed in 14% and 28% of patients receiving 0.05 and 0.10 mg/ kg/ day, respectively. 31 At a dose of 0.10 mg/ kg/ day the half life of rCD40L was 24.8 hours 31 . Based on these considerations and our experience with the initial two XHM patients, we initiated treatment of the three study XHM patients with rCD40L at a dose of 0.03 mg/kg on an alternate administration.
Restored T helper 1 (T H 1) function following rCD40L administration
We have previously shown that T cells from XHM patients are deficient in the production of TH1 effector cytokines following activation, and that this impairment in T cell function can be at least partially restored by the ex vivo addition of recombinant rCD40L. 24 To determine whether in vivo administration of rCD40L can drive naive XHM T cells to produce T H 1 cytokines, we cultured patient and control PBMCs with anti-CD3 (or with the superantigens SEA and SEB) for 36 h and then measured TNF-α or IFN-γ secreted into the culture fluid by specific ELISA. As shown in Figure 3A , prior to treatment with rCD40L, the patients' T cells exhibited markedly reduced levels of TNF-α and IFN-γ secretion to all three stimuli. However, 10 weeks after initiation of rCD40L treatment the T cells displayed increased capacity to produce both TNF-α
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From and IFN-γ, albeit still at a level below that produced by control cells. Furthermore, the capacity to produce these effector cytokines generally improved with the dose escalation step and persisted 10 weeks after rCD40L treatment had been stopped. We also assessed the ability of rCD40L treatment to prime CD4+ T cell subsets by measuring intracellular TNF-α and IFN-γ by flow cytometry after stimulation with anti-CD3/CD28 (Figure 3B) . Consistent with the ELISA results, prior to treatment the activated patient T cells were deficient in generating cells with intracellular TNF-α or IFN-γ. However, after 20 weeks of rCD40L treatment, cells positive for intra-cellular TNF-α and IFN-γ were found in both the CD4+ and CD8+ T cell subsets following stimulation with anti-CD3/CD28. These results demonstrate that in vivo rCD40L treatment can at least partially restore deficient T cell function.
Effect of rCD40L Treatment on Lymph Node Architecture
To assess the effect of rCD40L on lymph node architecture, we compared the histology of pretreatment and post-treatment tissue in one patient and examined post-treatment tissue in the other two patients (Figure 4) . Prior to treatment, all three patients lacked palpable axillary lymph nodes and little or no lymphoid tissue could be identified based on CT examination (Figure 5) .
One patient had an inguinal lymph node biopsy prior to rCD40L therapy that revealed small, scattered aggregates of IgM+/IgD+ B cells. However, no germinal centers were seen, and the B cells were primarily located in abortive follicles that contained only a scant follicular dendritic cells. This histological finding is similar to that described in previous studies of lymph nodes of XHM patients. 8, 34 For personal use only. on October 24, 2017. by guest www.bloodjournal.org From A substantially different picture was obtained at the end of rCD40L treatment when all three patients had easily visualized lymph nodes on CT examination (Figure 3 ). These were particularly evident in the axillary areas, possibly because the majority of rCD40L injections were given in the forearm. Biopsy and histologic examination of these nodes revealed prominent cortical primary follicles associated with a robust development of follicular dendritic cells (Fig   4) . However, as in the pre-treatment specimen, no germinal centers were observed, and only CD40L also interacts with CD40 on antigen presenting cells (APCs) to induce production of factors such as IL-12 and the expression of co-stimulatory molecules such as B7
that collectively mediate the differentiation and maturation of T cells. 10, 11, 37 Thus, failure to express CD40L results in impaired T cell function and increases the risk for opportunistic infections and malignancy. [12] [13] [14] Therefore, unlike pure humoral immune deficiencies associated with mutations in Bruton's tyrosine kinase (BTK) 38, 39 or activation-induced cytidine deaminase (AID), 40, 41 gamma globulin replacement therapy (IVIG) is less satisfactory for the management of XHM due to the significant T cell abnormalities. 13, 16 Despite gamma globulin substitution therapy the expected survival rate for XHM is less than 20% by the age of 25, emphasizing the need for new medical therapies for this disorder.
13
A clinical trial of one potential new therapy, subcutaneous administration of rCD40L, is reported here. Importantly, all patients were clinically stable during both 22-week treatment periods and the 12 week post-treatment follow-up. There were no serious adverse events and injection site reactions and these were effectively managed by site-rotation and occasional use of oral nonsteroidal anti-inflammatory agents.
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The rCD40L treatment regimen used in this study resulted in improvement in both T cell and B cell immunity.
All three patients demonstrated the capacity to mount delayed-type hypersensitivity (DTH) reactions to the recall antigen candida antigen and to develop a recall response to KLH. This latter response is significant because it was lost 8 weeks after discontinuation of rCD40L therapy and therefore appears to be directly linked to rCD40L therapy and not simply the result of booster immunization by repeated exposure to a recall antigen. Delayed-type hypersensitivity is a major mechanism of defense against various opportunistic infections including Pneumocystis jerovicii, Toxoplasma gondii, and
Cryptosporidium. Whether the degree of improved T cell function resulting from rCD40L treatment is sufficient to offer protection against these infections awaits further investigation. The expression of CD40L is tightly regulated on the surface of CD4 + T cells and constitutive expression of CD40L in mice led to the development of lymphomas that involved multiple organs 42, 43 . Although such adverse events were not noted in CD40L deficient mice that received murine rCD40L in a 450-day treatment study, XHM patients enrolled in future clinical trials that utilize rCD40L will need careful monitoring. At 0.05 mg/kg dose transient elevations in liver transaminases were noted in our study patients. While reversible, future studies of rCD40L
should incorporate frequent evaluations for liver toxicity. This leads to the question as to which group of patients should enroll into future studies involving rCD40L. Studies with the potential to offer clinical benefit should have priority. Cryptosporidium infection in XHM patients often leads to liver failure and hematopoietic stem cell transplantation (HSCT) in this setting is associated with poor clinical outcomes 44 . In light of improved T cell function resulting from rCD40L administration, rCD40L has the potential to be an important treatment option for XHM patients with biliary Cryptosporidium.
In conclusion, this "proof of principle" study of rCD40L therapy for XHM patients provides convincing evidence that such therapy is well tolerated in the doses utilized. rCD40L treatment resulted in a degree of reconstitution of T cell priming and T cell-mediated effector functions that could favorably affect patient resistance to opportunistic infection and immune surveillance for cancer. Thus, continued investigation of CD40 agonists in XHM and related disorders of B cell terminal differentiation is warranted.
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Mean survival times for the two groups treated with CD40L are significantly greater (p < 0.01) than the control group. Figure 2 . Development of positive delayed type hypersensitivity (DTH) reactions to KLH and Candida in the three XHM participants who received rCD40L. The patients were administered rCD40L subcutaneously three times per week at 0.03 mg/kg for 22 weeks, and after a 12 week drug free interval, the dose of rCD40L was increased to 0.05 mg/kg for an additional 22 weeks of treatment. Note the absent reactions during the drug free interval and the post-treatment period, indicating the positive results during rCD40L treatment period were not due to repeated skin testing. 
